These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34992111)

  • 1. CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
    Gengiah TN; Abdool Karim Q; Harkoo I; Mansoor L; Zuma NY; Radebe P; Samsunder N; Baxter C; Maharaj B; Baum MM; Moss JA; Pozzetto B; Hankins C; Abdool Karim S
    BMJ Open; 2022 Jan; 12(1):e052880. PubMed ID: 34992111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
    Mahomed S; Garrett N; Potloane D; Sikazwe IT; Capparelli E; Harkoo I; Gengiah TN; Zuma NY; Osman F; Mansoor L; Archary D; Myeni N; Radebe P; Samsunder N; Doria-Rose N; Carlton K; Gama L; Koup RA; Narpala S; Serebryannyy L; Moore P; Williamson C; Pozzetto B; Hankins C; Morris L; Karim QA; Abdool Karim S
    BMJ Open; 2023 Aug; 13(8):e076843. PubMed ID: 37640457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial.
    Naidoo A; Dooley KE; Naidoo K; Padayatchi N; Yende-Zuma N; Perumal R; Dorse G; Boodhram R; Osuala EC
    BMJ Open; 2022 Nov; 12(11):e067765. PubMed ID: 36356989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
    Mahomed S; Garrett N; Capparelli E; Baxter C; Zuma NY; Gengiah T; Archary D; Moore P; Samsunder N; Barouch DH; Mascola J; Ledgerwood J; Morris L; Abdool Karim S
    BMJ Open; 2019 Jul; 9(7):e030283. PubMed ID: 31272988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Castonguay AE; Webster P; Buser C; Moss JA; Trinh M; Beliveau M; Hendrix CW; Marzinke MA; Tuck M; Caprioli RM; Reyzer ML; Kuo J; Gallay PA; Baum MM
    Sci Rep; 2022 May; 12(1):8224. PubMed ID: 35581262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
    Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
    Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
    Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
    BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
    Huhn GD; Wilkin A; Mussini C; Spinner CD; Jezorwski J; El Ghazi M; Van Landuyt E; Lathouwers E; Brown K; Baugh B;
    HIV Res Clin Pract; 2020 Dec; 21(6):151-167. PubMed ID: 33528318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
    Mesplède T
    Expert Opin Pharmacother; 2021 Jul; 22(10):1245-1251. PubMed ID: 33691554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Kityo C; Hagins D; Koenig E; Avihingsanon A; Chetchotisakd P; Supparatpinyo K; Gankina N; Pokrovsky V; Voronin E; Stephens JL; DeJesus E; Wang H; Acosta RK; Cao H; Quirk E; Martin H; Makadzange T
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):321-328. PubMed ID: 31609930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.